FIELD: medicine.
SUBSTANCE: invention refers to medicine, particularly to endocrinology and ophthalmology, and can be used for treating endocrine autoimmune ophthalmopathy with underlying diffuse toxic goiter. Tyrosol is used in dose of 10 mg 3 times a day. Additionally, dalargin 0.1% solution is injected intramuscularly 2 times a day in dose of 1.0 ml for 30 days. Dalargin administration is repeated 3, 6 and 9 months after the beginning of the treatment.
EFFECT: invention provides highly effective treatment of endocrine autoimmune ophthalmopathy with underlying diffuse toxic goiter.
1 cl, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF ENDOCRINE OPHTHALMOPATHY TREATMENT | 2020 |
|
RU2725861C1 |
| METHOD FOR PREDICTING THE DEVELOPMENT OF RELAPSE IN THE MEDICAL TREATMENT OF GRAVES' DISEASE | 2021 |
|
RU2778614C1 |
| METHOD FOR ENDOCRINE OPHTHALMOPATHY EARLIEST MANIFESTATIONS DIAGNOSING | 2016 |
|
RU2617198C1 |
| METHOD FOR PREDICTION OF CLINICAL COURSE OF ENDOCRINE OPHTHALMOPATHY IN PATIENTS WITH GRAVES DISEASE BY DETECTING ANTI-THYROID PEROXIDASE ANTIBODIES | 2011 |
|
RU2460072C1 |
| METHOD FOR INDIVIDUAL PRESCRIPTION OF SYSTEMIC GLUCOCORTICOSTEROID PULSE THERAPY IN PATIENTS WITH ENDOCRINAL OPHTHALMOPATHY | 2012 |
|
RU2503011C1 |
| METHOD FOR TREATING ENDOCRINE OPHTHALMOPATHY | 2022 |
|
RU2791648C1 |
| METHOD OF TREATING HYPOTHYROIDISM WITH DALARGIN | 2023 |
|
RU2814749C1 |
| METHOD OF TREATING CHRONIC KIDNEY DISEASE WITH DALARGIN | 2023 |
|
RU2819638C1 |
| METHOD FOR EARLY DIAGNOSIS OF AN ACTIVE PHASE OF ENDOCRINE OPHTHALMOPATHY | 2018 |
|
RU2687082C1 |
| METHOD FOR PERSONALIZED APPROACH TO CHOOSING METHOD FOR TREATMENT OF GRAVES DISEASE | 2022 |
|
RU2794815C1 |
